Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Nature clinical practice. Oncology - 1 Nov 2005

Giaccone Giuseppe, Rodriguez Jose Antonio

Abstract excerpt

Tyrosine kinase inhibitors directed against the epidermal growth factor receptor (EGFR) are the first molecular-targeted agents to be approved in the US and other countries for the treatment of advanced non-small-cell lung cancer after failure of chemotherapy. Some patient characteristics, such as never-smoking, female gender, East Asian origin, adenocarcinoma histology, and bronchioloalveolar subtype, are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 16270096
DOI: 10.1038/ncponc0341

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR inhibitors: what have we learned from the treatment of lung cancer?PMID 16270096Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor inhibition in lung cancer: status 2012.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.Semantic proximity Read ↗

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned.Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.